Vaccinex, Inc. Share Price

VCNX

US9186403013

Biotechnology & Medical Research

Market Closed - OTC Markets 19:41:36 04/06/2026 BST			5-day change	1st Jan Change
1.000 ^USD	+29.45%		+21.88%	-7.02%

10-07	Vaccinex, Inc. Announces Publication of Results from Pilot Study Evaluating Pepinemab in Patients with Metastatic Melanoma	CI
07-08	Vaccinex, Inc. Reports New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in Alzheimer?s Disease	CI

News in other languages: Vaccinex, Inc.

25/09/23

MORNING BRIEFING - USA/Asien

More news

Managers and Directors: Vaccinex, Inc.

Manager	Title	Age	Since
Maurice Zauderer CEO	Chief Executive Officer	80	31/03/2001
Jil Sanchez DFI	Director of Finance/CFO	54	13/03/2024
Elizabeth Evans COO	Chief Operating Officer	54	10/05/2021

Director	Title	Age	Since
Maurice Zauderer BRD	Director/Board Member	80	31/03/2001
Albert Friedberg CHM	Chairman	79	31/03/2001
Jacob Frieberg BRD	Director/Board Member	69	31/01/2015

More insiders

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâ€™s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. It also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/11/26	US$0.7021	-6.39%	138

Real-time OTC Markets

More quotes

Market Cap	2.88M 2.57M 2.36M 2.15M 4.02M 273M 4.1M 28.17M 11.36M 144M 10.8M 10.57M 454M	P/E 2023	-0.21x	P/E 2024	-0.11x
Enterprise Value	1.8M 1.6M 1.47M 1.34M 2.51M 170M 2.56M 17.58M 7.09M 89.78M 6.74M 6.6M 284M	EV / Sales 2023	12.3x	EV / Sales 2024	2.56x
Free-Float	99.72%	Yield 2023 *	-	Yield 2024	-

10-07	Vaccinex, Inc. Announces Publication of Results from Pilot Study Evaluating Pepinemab in Patients with Metastatic Melanoma	CI
07-08	Vaccinex, Inc. Reports New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in Alzheimer?s Disease	CI
12-23	Vaccinex, Inc. Enters into a $60 Million Revenue Sharing Agreement with Pepinemab Development Venture, LP	CI
27/05/25	Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer At Asco Annual Meeting	CI
21/04/25	Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research	CI
15/04/25	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
14/04/25	Vaccinex, Inc. Auditor Raises 'Going Concern' Doubt	CI
19/03/25	Vaccinex, Inc. Announces Resignation of Bala S. Manian as A Director	CI
19/12/24	Vaccinex, Inc.(OTCPK:VCNX) dropped from S&P TMI Index	CI
17/12/24	Top Midday Decliners	MT
17/12/24	Vaccinex Stock to Be Delisted From Nasdaq	MT
16/12/24	Vaccinex, Inc.(OTCPK:VCNX) dropped from NASDAQ Composite Index	CI
18/11/24	Earnings Flash (VCNX) VACCINEX Reports Q3 Revenue $52,000	MT

10-07	SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study	AQ
07-08	Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026	AQ
04-30	Vaccinex Reports 2025 Annual Financial Results	AQ
12-23	Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease	AQ
12-03	Vaccinex : CTAD 2025 Oral Communication	PU

1 day	+29.45%
1 week	+21.88%
Current month	+33.33%
1 month	-0.99%
3 months	+18.25%
Current year	-7.02%

1 week	0.7	1
1 month	0.66	1.15
Current year	0.34	1.5
1 year	0.31	1.5
3 years	0.25	13.44
5 years	0.25	478.8
10 years	0.25	2,568.3

Vaccinex, Inc. Share Price

Stocks

VCNX

US9186403013

Biotechnology & Medical Research

Valuation: Vaccinex, Inc.

Chart: Vaccinex, Inc.

Latest news: Vaccinex, Inc.

Press Releases: Vaccinex, Inc.

News in other languages: Vaccinex, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Vaccinex, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/11/24	Maurice Zauderer	Other	Founder	46,153	1.6512%
14/11/24	Albert Friedberg	Other	Chairman	0	0%
14/11/24	Friedberg Mercantile Group Ltd. /Friedberg Family/	Other	Company	615,402	22.0164%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VACCINEX, INC.	+29.45%	+21.88%	+58.45%	-92.24%	1.88M
WUXI APPTEC CO., LTD.	-2.37%	-5.03%	+39.49%	+62.39%	62.23B
ARGENX SE	-0.10%	+0.10%	+10.40%	+68.30%	54.92B
LONZA GROUP AG	-0.31%	+1.51%	+19.70%	+96.11%	55.26B
IQVIA HOLDINGS INC.	-3.33%	-5.54%	+19.39%	+35.69%	42.59B
BEONE MEDICINES AG	-2.45%	-2.59%	+16.36%	+98.45%	41.08B
REVOLUTION MEDICINES, INC.	-1.64%	+2.32%	+219.80%	+789.69%	40.33B
GENMAB A/S	+0.14%	+23.72%	+98.87%	+83.56%	33.12B
CELLTRION, INC.	+0.21%	+1.05%	+14.81%	+46.96%	32.61B
INSMED INCORPORATED	-2.90%	+17.12%	-42.35%	+337.07%	23.98B
Average	+2.15%	+3.85%	+45.49%	+152.60%	38.61B
Weighted average by Cap.	-1.10%	+2.74%	+44.60%	+162.49%

	2023	2024
Net sales	570K 509K 467K 425K 796K 53.96M 812K 5.58M 2.25M 28.48M 2.14M 2.09M 89.96M	601K 537K 492K 448K 840K 56.9M 856K 5.88M 2.37M 30.03M 2.26M 2.21M 94.85M
Net income	-20.25M -18.08M -16.59M -15.09M -28.3M -1.92B -28.86M -198M -79.88M -1.01B -76M -74.38M -3.2B	-18.63M -16.64M -15.27M -13.89M -26.04M -1.76B -26.56M -182M -73.5M -931M -69.94M -68.44M -2.94B
Net Debt	-1.29M -1.15M -1.06M -960K -1.8M -122M -1.84M -12.6M -5.08M -64.36M -4.83M -4.73M -203M	-1.08M -966K -886K -806K -1.51M -102M -1.54M -10.59M -4.27M -54.07M -4.06M -3.97M -171M